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We conducted a series of experiments using mouse immune-precursor cells, and observed that
bioreactor culturing results in the loss of antigen-specific cytotoxic T lymphocyte (CTL) function.
The reason for the abrogation of CTL function is microgravity conditions in the bioreactor, but not the
antigen per se or its MHC restriction. Similarly, we observed that allostimulation of human PBMC in
the bioreactor, but not in the T flask, resulted in the blunting of both allo-CTL function and the NK
activity, indicating that the microgravity-associated functional defects are not unique to the mouse
system. These results provide further confirmation to the microgravity-associated immune
dysfunction, and constitute ground-based confirmatory data for those related to the space-travel.
The following is a detailed summary of the results of the entire project study:
We employed a novel mouse model developed in our laboratory that uses non-infections
synthetic peptides for in vivo induction of CTLs capable of killing ceils infected with infections
viruses (17-23). The major goal was to test whether the rotating bioreactor technology will be
superior to conventional tissue culturing for expansion of cytotoxic T lymphocyte (CTL) precursors.
Towards this goal, we have immunized Balb/c mice (expressing the MHC class I haplotype H-2 a)
with a synthetic peptide from the immunodominent V3-1oop region of the envelope protein gp 120 of
the human immunodeficiency virus type 1 (Hrv-1). This peptide has previously been shown in our
laboratory to be capable of inducing efficient CTL response directed against syngeneic target cells
expressing the HIV-1 envelope protein, in the mouse model (17-21). After a 7 d period subsequent to
intradermal immunization in the hind foot pad, mice were sacrificed and the draining popliteal lymph
nodes (PLN) were surgically removed. Ceils obtained from the PLN were restimulated for 5 d in the
presence of irradiated syngeneic mouse spleen cells that were preincubated with the HIV peptide for 2
h at 37 C. For the restimulation, equal numbers of cells were cultured in the slow-turning lateral
vessel (STLV), the high-aspect rotating vessel (HARV) or, in the tissue culture flask (T flask). At the
end of the 5 d restimulation, cells were washed, counted and tested for cytolytic activity against
syngeneic p815 cells that were either preincubated with medium alone or in the presence of the HIV
synthetic peptide. Data presented in Fig. 1 clearly demonstrates that while T flask cultures showed
high levels of antigen-specific CTL activity, those cultured in either STLV or HARV showed
complete abrogation of the CTL activity. Similar results showing abrogation of antigen-specific CTL
activity in bioreactor cultures were obtained when the experiment was repeated with a CTL epitope
peptide (I-I-2a-restricted) from a different virus, lymphocytic choriomeningitis virus (LCMV). These
data from experiments employing HIV and LCMV peptides strongly suggest that the abrogation of
CTL function is not unique to the peptide antigen employed.
We then sought to verify whether the MHC haplotype expressed by the mouse strain is a
contributing factor for the observed abrogation of CTL activity. We conducted experiments in
C57BL/6 mice which express the H-2 ° haplotype, using a peptide, E31, corresponding to the E6
oncoprotein of human papillomavims type 16 (HPV-16), that we previously demonstrated to be
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capable of inducing CTL (22). Restimulation of CTL precursors from E31-immunized C57BL/6 mice
in the bioreactors drastically reduced the peptide-specific CTL activity, while those cultured in the T
flask showed significant activity (Fig. 2). To further confuan that neither the antigen (i.e. peptide) nor
the host MHC (i.e. the H2 haplotype) are the potential contributors for abrogation of CTL function.
We immunized a hybrid mouse strain, CB6F1 that expresses H-2 TM, with a mixture of 5 synthetic
peptides corresponding to immunogenic proteins from five different viruses (HIV-1, HPV-16,
LCMV, Influenza, and Sendal virus). Once again, restimulation of immune lymph node cells by
culturing in the T flask with the peptide mixture resulted in elaboration of CTL activity specific to each
of the peptides, while cultures from the bioreactor were completely devoid of CrL activity specific to
any of the five peptides (Fig. 3). These results from studies in multiple mouse strains employing a
variety of antigenic peptides clearly establish that the rnicrogravity culturing of immune precursor cells
in the bioreactors as responsible for the abrogation of antigen-specific CTL activity.
In an attempt to begin understanding the basis for the abrogation of CTL function of the
cultures subjected to growth in the bioreactors, we first analyzed for differences in cell viability
between the two growth conditions (Table 1). Overall, bioreactor cultures showed significantly lower
viable cell populations (p = 0.05). A comparison of FACS analysis data from three different
experiments presented in Table 1 indicates that the loss of CTL function in bioreactor cultures is not
associated with changes in the viability of the CDS+ effector ceil populations. We also did not
observe significant differences in the numbers of viable cells expressing DEC-205, the receptor on
dendritic ceils which are known to function as potent antigen presenting cells (APC). on the other
hand, a significant reduction was observed in the CD4+ cells (p = 0.05). Further systematic
comparative analysis of cellular phenotype and functional properties of various cell types is required
for a better understanding of the basis of microgravity-associated immune dysfunction.
We also conducted studies using human PBMC to test whether the functional defects we
observed in mouse immune cells resulting from bioreactor culturing are unique to the mouse system.
Specifically, we analyzed for differences in NK cells, and alloreactive CTL after stimulating the cells
in either T flask or the bioreactor for seven days. Results presented in Fig. 4 clearly indicate that both
the NK and allo-CTL function are severely compromised by culturing in the bioreactor. These results
provide further confnmation to the microgravity-associated immune dysfunction, and also constitute
ground-based cortfinnatroy data for those observed in astronauts and cosmonauts after both short-
and long-duration space travel.
More recently, we were successful in adopting an in vitro immunization protocol (see methods
section for details) for generating antigen-specific T cell responses with human PBMC (Table 2). In
these studies, we have cultured DC isolated from human peripheral blood samples in vitro in the
presence of GM-CSF and IL-4, and pulsed with synthetic peptides from highly conserved regions in
the envelope protein gpl20 of HIV-1. Subsequently, these cells were co-cultured with autologous
lymphocytes. The resulting activated lymphocytes exhibited predominantly T cell phenotype, and
showed efficient proliferative responses specific to the cognate HIV peptides. Such an in
protocol efficient in priming primary immune response specific to given antigen will have direct
clinical utility in terms of fortifying immune responses in cases where body's natural capacity to
mount an effective immune response is compromised. We plan to test whether the bioreactor
technology, by virtue of its capacity to create 3D and in vivo -like environment, provides any benefits
to enhance any of the aspects of this in _ immunization protocol.
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Fig. 1. Effect of microgravity culturing on the CTL
activity of lymph node cells from Balb/c mice
immunized with a synthetic peptide from the envelope
protein of HIV-1
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Fig. 2. Effect of microgravity culturing on the CTL
activity of lymph node cells from C57B1/6 mice
immunized with a synthetic peptide from the E6
oncoprotein of HPV-16
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Fig. 3. Effect of microgravity culturing on the CTL
activity of lymph node cells from CB6F1 hybrid mice
immunized with a mixture of synthetic peptides from
five viruses
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Fig. 4. Effect of microgravity culturing on the
cytolytic function of human periferal blood
mononuclear cells
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1. Analysis of immune lymph node cells from Balb/c mice
Growth Condition Total Cells CD4-CeUs CD8-Cells Dendritic Cells
Surviving (%) (%) (%) •(%)
2D-Cultures
Experiment I 27.9 32.1 48.5 26.2
Experiment 2 53.7 39.7 10.1 49.1
Experiment 3 43.6 48.4 23.9 15.7
Average 41.73 + 13" 40.07 + 8.2 27.5 + 19.5 30.33 + 17.1
3D-Cultures
Experiment 1 18.2 24.3 45.5 15.4
Experiment 2 20.5 31.9 8.9 37.8
Experiment 3 25.0 28.9 5.3 8.9
Average 21.23 + 3.5 28.37 + 3.8 19.9 ± 22.2 20.7 ± 15.2
p ** = 0.05 0.05 0.28 0.28
* Standard Error; ** Mann-Whitney U
Table: 2. Proliferative responses of T cells primed by in _ immunization with HIV peptides
Treatment Proliferative Response (SI)
Medium 1.0
PHA 5.6
PPD 5.4
HIV peptides 10.2
Based on our pilot data, we hypothesize that the NASA bioreactor technology offers an
efficient means to mimic and explore the mechanistic basis for the apparent immunodeficiency related
to space-lravel. It is important to determine the correlates to defects in effector T cell function resulting
from RWV-culturing of immune effector cells from mice and humans. Comparative analysis should
be conducted to determine: (i) the qualitative and quantitative differences in populations of various
effector T cells (TH and CTL) and accessory cells (APC like dendritic cells), (ii) the accessory cell
functions (antigen presentation by DC, and proliferation and cytokine production by TH cells), and
(iii) the signal transduction mechanism involving the 3AK-STAT molecules. Similar studies can be
conducted with the human samples, but focusing initially on comparing allo-CTL and NK activities of
.cells cultured in the T flask and bioreactor. Subsequently, these two culturing protocols can also be
compared for in _ priming of synthetic peptide-specific T cell responses. For these experiments,
DC isolated from human blood samples can be pulsed with synthetic peptides from HIV and HPV
before co-culturing with autologous T cells either in T flask or bioreactor.
Since there are interesting parallels to microgravity-associated immune dysfunction in immune
disorders like HIV-AIDS, and HPV-associated cervical cancer, we believe that the RWV technology
for ex vivo manipulation of immune effector cells, yet mimicking immunological abnormalities
observed in vivo, can provide valuable basic information about immune dysfunction related to these
respective vires. Future studies in microgravity research should help expand the applicability of the
NASA-bioreactor technology beyond the space science, to medicine, for developing strategies to
efficiently prime, supplement, and reconstitute CMI responses against these immune disorders.
